-
Innovation Ranking
NewInnovation Ranking – CSPC Pharmaceutical Group Ltd
CSPC Pharmaceutical Group Ltd (CSPC) is a pharmaceutical company, which provides innovative, generic and bulk drugs. The company manufactures, research and markets medicines and pharmaceutical related products. CSPC product portfolio includes capsules, tablets, injections, caffeine and antibiotics such as acarbose, penicillin sodium, cefazolin sodium and meropenem. The company offers its products for various diseases including ovarian cancer, breast cancer, hypertension and leukemia. Its drugs focus on major therapeutic areas such as neurology, diabetes, cardio-cerebrovascular, oncology and anti-infective. The company operates...
-
Company Insights
Innovation and Patenting activity of CSPC Pharmaceutical Group Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of CSPC Pharmaceutical Group Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – DP-303c in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DP-303c in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DP-303c in Gastric Cancer Drug Details: DP-303c is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – DP-303c in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DP-303c in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DP-303c in Adenocarcinoma Of The Gastroesophageal Junction Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bentracimab in Bleeding And Clotting Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bentracimab in Bleeding And Clotting Disorders report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bentracimab in Bleeding And Clotting Disorders Drug Details: Bentracimab (PB-2452...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Divarasib in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Divarasib in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Divarasib in Pancreatic Cancer Drug Details: Divarasib (GDC-6036 (RG6330)) is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MK-3475A in Squamous Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MK-3475A in Squamous Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MK-3475A in Squamous Non-Small Cell Lung Cancer Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Atamparib in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Atamparib in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Atamparib in Breast Cancer Drug Details: Atamparib (RBN-2397) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Paclitaxel Albumin Bound in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Paclitaxel Albumin Bound in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Paclitaxel Albumin Bound in Triple-Negative Breast Cancer...